MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors

MHB048C is an investigational antibody–drug conjugate designed to target prostate‑specific membrane antigen (PSMA) on tumor cells and selectively deliver a DNA topoisomerase I–inhibiting cytotoxic payload. By combining a PSMA‑directed antibody with a potent payload, the drug aims to exploit the high and relatively restricted expression of this surface antigen in advanced prostate cancer and in subsets of other solid tumors, while limiting systemic exposure to free drug. This strategy reflects a broader shift in solid‑tumor oncology toward precision cytotoxic delivery, seeking to preserve or even enhance the potency of classic chemotherapeutic mechanisms but confine their effects primarily to malignant tissue.​

The first‑in‑human clinical development of this molecule is taking place in China in a Phase 1/2 trial enrolling adults with metastatic castration‑resistant prostate cancer and other advanced solid tumors for which standard therapies have been exhausted or are not suitable.

From a clinical‑science perspective, MHB048C sits at the intersection of two proven concepts in prostate oncology: PSMA as a validated target and topoisomerase I inhibition as a potent means of inducing DNA damage. PSMA is widely exploited for imaging and for radioligand therapy in metastatic castration‑resistant disease, and its enrichment on tumor cells relative to most normal tissues makes it an attractive anchor for ADC development. By tethering a topoisomerase I inhibitor to a PSMA‑binding antibody, MHB048C aims to internalize the conjugate upon receptor engagement, release the payload intracellularly, and generate lethal DNA strand breaks preferentially within PSMA‑expressing cells. The theoretical advantages of such a design include higher effective intratumoral drug concentrations, potential bystander effects in antigen‑heterogeneous lesions if the payload can diffuse locally, and mitigation of off‑target systemic exposure that limits the use of free topoisomerase inhibitors.​

Clinical trial.